Introduction
Acute myeloid leukaemia (AML) arises from malignant leukaemic stem and progenitor cells (LSPC). These cells are capable of self-renewal and have an abnormal programme of differentiation. In AML, these LSPCs can be uniquely immunophenotyped as overexpressing CD123, CD33 and a number of other markers (leukaemia-associated phenotypes (LAPs)) on CD34 þ CD38 À cells. [1] [2] [3] [4] These distinguishing features of LSPC phenotype compared with normal bone marrow stem cells has facilitated the characterization of minimal residual disease in AML. In fact, the CD34 þ CD38 À CD123 þ /CD33 þ LSPC contain the subpopulation, which is capable of repopulating NOD/SCID mice. 1, 3, 4 The persistence of LSPC in the bone marrow of AML patients post induction/consolidation chemotherapy is thought to mediate disease relapse, which occurs in 450% of patients who achieve complete remission. We have recently established a standardized quantitative scale for determining a CD34 þ
CD38
À CD123 þ LSPC phenotype. 5 In trying to mimic the in vivo scenario, factors underpinning relapse in AML, such as LSPC burden, bone marrow niche microenvironment and other prognostic factors (such as FLT3 status) need to be modelled in vitro so as to understand the contributory factors that allow LSPC survival post chemotherapy. This is important to help identify appropriate therapeutic interventions that achieve lasting remissions in AML.
We have previously established a short-term culture system in a defined 'niche-like' microenvironment, which allows enumeration of viable LSPC after treatment with chemotherapeutic agents. 5 Using this system, we found the survival of the LSPC subset to be enhanced rather than inhibited after treatment with the FLT3 inhibitor AG1296. 5 In the current study, we have used the system to screen the effectiveness of Mylotarg against LSPC.
Mylotarg (gemtuzumab ozogamicin) is an antibody-targeted chemotherapeutic agent consisting of the humanized CD33 antibody to which calicheamicin-g1 is attached. 6 CD33 targeting by Mylotarg is specific to leukaemic cells, as 90% of AML samples overexpress CD33 on blast cells 7, 8 and LSPC 2, 3 but the antigen is absent or expressed at low levels on normal haemapoietic stem and progenitor cells (HSPC) and nonhaematological tissues. 9, 10 Once Mylotarg is internalized, the calicheamicin-g1 itself is able to intercalate within the minor grooves of DNA causing double-strand breaks and cell death.
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In the United States, in 2000, approval for Mylotarg was obtained by Food and Drug Administration for patients with relapsed AML who are older than 60 years of age and who are considered unfit for conventional cytotoxic therapy. 6 In the United Kingdom, preliminary clinical data from the MRC (Medical Research Council) AML 15 trial indicate that patients below 60 years of age who are randomized to Mylotarg induction, in addition to conventional chemotherapy, showed improved disease-free survival. 12 Both CD33 expression and P-glycoprotein (Pgp) proteinmediated drug efflux have been shown to be inversely correlated and predictive of clinical outcome in patients with AML treated with Mylotarg. 13 As Mylotarg is showing promise in the clinic, the current study was designed to assess LSPC response to Mylotarg and to determine the extent to which factors such as FLT3 status, CD33 expression levels, LSPC burden and Pgp status cooperate to determine patient heterogeneity in chemosensitivity to Mylotarg.
Materials and methods

Cell samples
Blood or bone marrow samples were obtained after written informed consent from AML patients and healthy stem cell donors. Use of these samples was approved by the Ethics Committee of the Nottingham University NHS Trust. Mononuclear cells were isolated using a standard density gradient/ centrifugation method with histopaque, and red blood cells were depleted from the sample using ammonium chloride. Normal donor stem cell harvests were enriched for CD34 þ cells using CD34 Miltenyi MicroBead Kit (Woking, Surrey, UK).
Materials
Recombinant cytokines were obtained from R&D Systems (Abingdon, UK). All antibodies were from Becton Dickinson (Cowley, UK). Unless otherwise stated, all chemicals were purchased from Sigma (Poole, UK). Mylotarg was kindly provided by Wyeth Pharmaceuticals (Pearl River, NY, USA).
Cell culture
Fibronectin-coated wells and serum-free medium were used as previously described. 5 For the maintenance of LSPC phenotype in 48-h culture, we treated 21 AML samples in serum-free medium with immobilized fibronectin along with a combination of cytokines consisting of IL-3 (interleukin-3) (20 ng/ml), SDF-1 (stromal cell-derived factor 1) (100 ng/ml), SCF (stem cell factor) (50 ng/ml) and TPO (thrombopoietin) (50 ng/ml). For the chemosensitivity assay, Mylotarg was reconstituted in water (1 mg/ml) and then diluted fresh in serum-free medium (10 ng/ml) when used.
Flow cytometry
Chemosensitivity assays and immunophenotyping. Flow cytometric enumeration of LSPC and bulk AML cells, as well as CD123 mean fluorescence intensities (MFI) were measured in CD34 þ CD38 À leukaemic samples as previously described. 5 Briefly, two flow cytometric analyses were used in parallel for the analysis of LSPC survival. One assay allowed reproducible measurement of the concentration of viable cells at the end of the experiment using 10 mg/ml 7-amino-actinomycin D and fixed CD45-stained normal mononuclear cells as internal standard. 14 The second assay allowed the determination of the percentage of LSPC within the viable population using CD34 FITC (CD34 fluorescein isothiocyanate), CD38 APC (CD38 allophycocyanin), CD123 PE (CD123 phycoerythrin) and (or isotype controls) with 7-amino-actinomycin D. From these two analyses, we calculated the concentration of LSPC from the proportion of viable cells that are
Viability levels for each sample were normalized to untreated control specimens. CD33 (PE) MFI in bulk and CD34 þ CD38 À leukaemic cells were also assessed as in the CD123 protocol (see above). Using the system previously established for CD123, 5 CD33 MFI values were compared with those of CD34 þ CD38 À cells from healthy donor samples and cutoff points were established to verify leukaemic nature of samples assessed. When CD123 and CD33 MFI values failed to reach the cutoff points, leukaemia-associated phenotypes were used to certify the leukaemic nature of the sample used. 4 Pgp status. The Pgp protein was measured using flow cytometric methodology as previously described. 15 Briefly, MRK-16 anti-Pgp (Kamiya Biomedical, Seattle, WA, USA) was used with a FITC-conjugated second layer. For bulk cells, leukaemic blasts were identified with a CD45 PerCP counterstain. For LSPC, the cells were counterstained with CD34 PerCP and CD38 APC. As Pgp is weakly expressed, the FL2 channel was deliberately avoided to exclude spectral overlap.
FLT3 status. Internal tandem duplication (ITD) of the FLT3
gene (FLT3/ITDs) were analysed by previously described methods. 16 ITD mutations were confirmed by analysis on a 3130 Genetic Analyser (Applied Biosystems, Warrington, Cheshire, UK) following PCR with a 5 0 -6-carboxyfluorescein (FAM)-labelled primer.
Statistics
Statistical analyses were performed with SPSS software (v16.0 licensed to The University of Nottingham UK) using the Wilcoxon signed rank test, multivariate (stepwise regression) analysis or Mann-Whitney test. Correlation studies were performed using Spearman's r correlation coefficient analysis with SPSS software. All data presented are mean or median ± s.d.
Results
Inclusion of primary AML sample in this study
As the expression of CD123 and CD33 is known to be elevated on leukaemic stem cells compared with that on their normal counterparts, [1] [2] [3] we established the nature of the CD34 þ CD38 À stem cell compartment by comparing the frequency of CD34 þ CD38 À cells and their expression of CD123, CD33 or leukaemia-associated phenotypes. Using previously established cutoff points from normal donor stem cell samples, 5 21 primary AML samples that overexpressed one or both of these markers were included in this study (Table 1) .
Chemosensitivity to Mylotarg
The in vitro model consists of immobilized fibronectin and the cytokines IL-3, SCF, TPO and SDF-1 to support the survival of LSPC in culture without the loss of phenotype (Supplementary Table 1 ). The addition of 10 ng/ml Mylotarg to the leukaemia cell culture for 48 h resulted in a mean % bulk cell kill of 13.84 ± 13.73% and mean % LSPC kill of 33.92 ± 22.52%. There was great heterogeneity in response to Mylotarg by LSPC ( Figure 1 ). Overall, although Mylotarg is capable of targeting both cell compartments, 16/21 (76%) LSPC showed elevated cell kill compared with bulk cells (P ¼ 0.003; Figure 2a ).
To assess cytotoxicity to normal HSPC, five normal donorderived CD34 þ CD38 À cell subsets from healthy individuals were also examined for differential response to Mylotarg. In contrast to leukaemic cells, normal HSPC were not killed by 10 ng/ml Mylotarg treatment (P ¼ 0.001, mean % HSPC kill was À12 ± 34.95%; Figure 2b ).
CD33 levels on bulk cells correlated with CD33 levels on CD34
þ CD38 À cells
The CD33 expression cutoff point was 7.63, and we found the expression of CD33 on the CD34 þ CD38 À cells in leukaemic samples to be highly variable (median ¼ 13.04, range ¼ 0.47-436.73, n ¼ 21; Table 1 ). As shown in Figure 3a , with the exception of two samples (AML nos. 1 and 4), which showed elevated CD33 expression on the CD34 þ CD38 À cells compared with CD33 bulk cell expression and two samples (AML nos. 6 Table 1 . LSPC concentrations are shown per ml of cells. Sensitivity to Mylotarg by stem cells in AML M Jawad et al expression in both cell compartments. Overall, there was a significant correlation between CD33 expression levels on bulk and on CD34 þ CD38 À cells (r ¼ 0.90, Po0.0001, n ¼ 21; Figure 3a ).
CD33 levels and Pgp status affect LSPC response to Mylotarg
The heterogeneity in Mylotarg response exhibited by the LSPC fraction in these AML samples (Table 1; Figure 1 ) suggests the presence of factors that may be acting to modulate chemosensitivity to Mylotarg. CD33 expression 2,3 and Pgp 13 have both been reported to influence Mylotarg sensitivity at the bulk cell level. We found a significant direct correlation between CD33 MFI levels on the CD34 þ CD38 À cells and chemosensitivity of LSPC to Mylotarg (r ¼ 0.70, Po0.0001, n ¼ 21; Figure 3b ).
Where sufficient material was available, we assessed the Pgp status in our samples to try and further understand heterogeneity in Mylotarg response amongst these samples. Of the 21 samples, 12 were assessed for Pgp status of the CD34 þ CD38 À cells and these were found to reflect the Pgp status of the bulk cell compartment (r ¼ 0.872, Po0.0001; Table 2 ). Our results are in line with previous studies in which a difference in Pgp levels between mature CD34 À bulk and immature CD34 þ primary cells was not observed. 16 Interestingly, although only 21 samples have been included in this study, data on an expanded cohort of samples (n ¼ 58), including samples with too few LSPC for chemosensitivity analysis, indicate that Pgp status and the % CD34 þ CD38 À cells are correlated (r ¼ 0.28, P ¼ 0.037). In line with this and as previously suggested from studies in bulk AML cells, 13 the 14/21 LSPC samples that exhibited a negative Pgp status profile showed enhanced sensitivity to Mylotarg compared with the Pgp-positive samples in which Mylotarg would be expected to be effluxed out of the cells. The % LSPC kill in Pgp-negative samples was 42.91 ± 19.37% (n ¼ 14) compared with 15.94±17.66% in Pgp-positive samples (n ¼ 7) (P ¼ 0.008; Figure 4a ). 
LSPC burden and FLT3/ITD status affects Mylotarg response
We then examined the effect of LSPC burden on Mylotarg response and found that the percentage of LSPC indirectly influenced Mylotarg sensitivity. The higher the LSPC burden at the start of the assay the less responsive these cells were to Mylotarg treatment (r ¼ À0.60, P ¼ 0.004, n ¼ 21; Figure 4b ). With a % LSPC median of 7.8%, 10/21 samples exhibited low LSPC burden (% LSPC kill was 48.07±15.92%), whereas 11/21 exhibited an elevated LSPC burden (% LSPC kill was 21.05±20.10%), showing significant difference in LSPC kill by Mylotarg (P ¼ 0.007; Table 1 ). Activating FLT3/ITD is predictive of early relapse 17 and poor prognosis 18, 19 in AML. In addition, FLT3/ITD mutations are known to be present in leukaemic stem cells. 20 Therefore, we assessed the FLT3 status in our samples and examined Mylotarg response in these samples. As shown in Table 1 , 13/21 (62%) samples were found to be FLT3/ITD and these were consistently found to be more sensitive to Mylotarg compared with FLT3/WT cells: FLT3/ITD mean % LSPC kill was 44.77 ± 16.81% compared with FLT3/WT mean % LSPC kill of 16.29±19.76% (P ¼ 0.006, n ¼ 21; Figure 4c ).
LSPC burden, Pgp status, CD33 expression levels and FLT3 status as prognostic markers for response to Mylotarg
Our data suggest that no single factor can predict Mylotarg response and that LSPC burden, Pgp status, CD33 expression levels and FLT3 status may all cooperate to influence the outcome in response to Mylotarg and thus determine the heterogeneity observed in chemosensitivity to Mylotarg in our cohort of AML samples. However, as some of these factors intercorrelated, we performed multivariate analysis and found that LPSC burden and FLT3 status are the only two factors that remained significant as predictors of LSPC chemosensitivity to Mylotarg treatment (Po0.0001). The mean % LSPC kill from samples that have low % LSPC burden and/or FLT3/ITD status was 43.31 ± 16.67% (n ¼ 16) compared with 3.87 ± 3.30% from all other samples (n ¼ 5) (P ¼ 0.001; Figure 5a ). However, in further assessing the involvement of FLT3 status, Pgp status, % LSPC and the levels of CD33 expression on the CD34 þ CD38
À cells on Mylotarg response by LSPC, patients with the combined characteristics of high CD33, Pgp-negative, FLT3/ITD and low % LSPC were most sensitive to Mylotarg (P ¼ 0.002; Figure 5b ; Patients nos. 4, 6, 11, 13 and 21 from Table 1 ), suggesting that cells from those patients benefit significantly more from Mylotarg treatment than all other samples.
Discussion
The characterization of agents that specifically target the cells that cause relapses, that is, the LSPC, is essential to achieve complete eradication of minimal residual disease cells in AML.
In the clinic, the addition of Mylotarg to conventional chemotherapy treatment results in increased disease-free survival in AML. 12 Therefore, we hypothesized that the efficacy of this agent may be due to LSPC targeting. In this study, the cytotoxic effect of Mylotarg on % LSPC survival was assessed in 21 primary AML samples grown under a defined bone marrow 'niche' microenvironment consisting of immobilized fibronectin, IL-3, SCF, SDF-1 and TPO. This simplified and defined microenvironment is able to maintain LSPC survival without differentiation and thus enable optimal assessment of drug toxicity. Under such conditions, we found a selective cytotoxicity on LSPC by Mylotarg, whereas normal HSPC were unaffected. However, LSPC response to Mylotarg was highly heterogeneous. Whereas previous studies 21, 22 investigating LSPC in vitro chemosensitivity have emphasized differences between LSPC and bulk cells, ours is the first study to show that there is inter-patient heterogeneity within the LSPC Sensitivity to Mylotarg by stem cells in AML M Jawad et al compartment. Our rationale for using a short-term in vitro culture system rather than a long-term or in vivo system was twofold: first, Mylotarg is already in clinical use and therefore evaluation of its effects in vivo has already taken place. Second, in contrast to more elaborate systems, most samples survive for 48 h under our experimental conditions and therefore we can build up a broad picture of factors underpinning inter-patient heterogeneity. We also set out to understand some of the factors that may affect this. We characterized the influence of LSPC burden, CD33 expression, Pgp and FLT3 status and their combination on LSPC response to Mylotarg. Taking these factors in consideration will help focus future work on combining Mylotarg with other agents that may enhance its efficacy.
Our data indicate that FLT3 status affected Mylotarg response and that LSPC from FLT3/ITD samples were more sensitive to Mylotarg compared with FLT3/WT samples. Interestingly, this observation did not apply at the bulk cell level (data not shown). This is the first study that has analysed the effect of FLT3 status on Mylotarg response. As for Pgp status, there is an acceptable general consensus that functional Pgp drug efflux inversely correlates with Mylotarg-induced toxicity. 23, 24 We found the same correlation with Pgp status in this study. Another interesting finding is the correlation between Pgp status in bulk cells and % CD34 þ CD38 À cells in a sample, particularly as both have been associated individually with poor prognosis in AML. 25, 26 The relationship between CD33 level and Mylotarg toxicity on AML blast cells has been explored widely with evidence for 13, 27 and against 24, 28 this relationship. We have shown a direct correlation between CD33 levels on the CD34 þ CD38 À cells and Mylotarg response. Although our in vitro data is in agreement with Mylotarg being administered to CD33 þ AML patients, 29, 30 our multivariate analysis suggests that LSPC burden and FLT3 status are the most important prognostic predictors of Mylotarg response by LSPC. This observation may help to explain why in some studies CD33 levels could not be correlated with Mylotarg response. 24, 28 The observed inverse correlation between LSPC burden and chemosensitivity to Mylotarg may indicate that LSPC may themselves be secreting factors that promote apoptosis resistance and that the density of the LSPC (higher LSPC burden in some samples) may affect neighbouring cells by promoting their survival, particularly in our 'niche' setting. A paracrine effect on blast survival has previously been suggested in the context of survival-related proteins such as bcl-2, which decrease with blast cell concentration after remission-induction chemotherapy, even in patients who subsequently relapse. 31 This study indicates that Mylotarg may need to be administered in addition to agents that reverse Pgp and/or CD33 negativity so that maximal benefit of Mylotarg cytotoxicity is achieved. For example, the addition of the Pgp inhibitor cyclosporine A has been shown to significantly enhance in vitro Mylotarg-induced cytotoxicity even in primary AML samples with low Pgp activity. 23 CD33 expression levels have also previously been modulated by cytokines such as Granulocyte colony-stimulating factor (G-CSF), in which increase in CD33 þ blast numbers increased in response to G-CSF treatment. 32 In fact, G-CSF has also been shown to cause an in vitro dose-dependent inhibition of Pgp function in Mylotargsensitive cell lines and in primary blast cells. 33 Thus, there is a rationale to assess the combination of Mylotarg with G-CSF. Indeed a recent study has looked into in vitro pretreatment with G-CSF and found that it could sensitize previously Mylotargresistant primary AML blasts. 33 Likewise, there is the potential of combining Mylotarg with CD33 modulators and assessing which patients may (or not) benefit from such a regimen. For example, the hypomethylating agent 5-azacytidine is known to increase CD33 expression sensitizing cells to Mylotarg treatment, 34 and our laboratory data strongly support the use of 5-azacytidine in combination with Mylotarg to achieve better cell kill. 35 The result of multivariate analysis suggests that LSPC burden and FLT3 status are the main predictors of Mylotarg response in our cohort of patients. Overall our results offer insights into the results of the MRC AML 15 trial, 12 which showed that addition of Mylotarg to induction chemotherapy results in reduced relapse rate and therefore enhanced disease-free survival. We suggest that CD33, Pgp and FLT3 status be assessed together as prognostic markers in the planning of any future clinical trials with Mylotarg for the treatment of AML. 
